glp-1 gout SGLT2 Inhibitors, but Not Receptor Agonists, Reduce Incidence of in People Living With Type 2 Diabetes Across the Therapeutic Spectrum Glucagon-like peptide-1 receptor agonists in

Alberta Blue Cross states that while a semaglutide generic is expected in mid-2026, growing use and continued expansion of GLP-1 therapies will offset savings [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]

shifting to plant-based diets can reduce that quickly

These days I consider myself a science-minded beauty journalist unafraid of interrogating iffy claims put forward by products, brands and personalities

Notably, only one study employed the gold standard of dietary intake measurement the 24-hour dietary recall

Automated topology builder Version 3.0: prediction of solvation free enthalpies in water and hexane

Consult your healthcare provider before using this or any product if you are taking medication or have a medical condition